Lasofoxifene in Postmenopausal Women With Osteoporosis
S. R. Cummings(University of California, San Francisco), Richard Eastell(University of Sheffield), Slobodan Vukičević(University of Zagreb), Kristine E. Ensrud(University of Minnesota), Roy A. Armstrong(Anna Needs Neuroblastoma Answers), Steven R. Goldstein(New York University), A. Lee(Anna Needs Neuroblastoma Answers), Andrea Z. LaCroix(Human Longevity (United States)), Patrick Neven(KU Leuven), Pierre D. Delmas(Inserm), David D. Thompson(Pfizer (United States)), U. Sriram(Anna Needs Neuroblastoma Answers), T.J. Powles(Royal Marsden NHS Foundation Trust), David M. Reid(University of Aberdeen), DL Kendler(Anna Needs Neuroblastoma Answers), John R. Thompson(University of Leicester), José Zanchetta(Universidad del Salvador)
Cited by 25
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
A framework for the investigation of pleiotropy in two‐sample summary data Mendelian randomization
|Statistics in Medicine|2017|2k
Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome
|Statistics in Medicine|2015|1.8k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k